ECSP088262A - ALBUMIN FUSION PROTEINS - Google Patents

ALBUMIN FUSION PROTEINS

Info

Publication number
ECSP088262A
ECSP088262A EC2008008262A ECSP088262A ECSP088262A EC SP088262 A ECSP088262 A EC SP088262A EC 2008008262 A EC2008008262 A EC 2008008262A EC SP088262 A ECSP088262 A EC SP088262A EC SP088262 A ECSP088262 A EC SP088262A
Authority
EC
Ecuador
Prior art keywords
albumin fusion
fusion proteins
vectors
host cells
methods
Prior art date
Application number
EC2008008262A
Other languages
Spanish (es)
Inventor
Craig Rosen
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of ECSP088262A publication Critical patent/ECSP088262A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención comprende proteínas de fusión de albúmina. Las moléculas de ácido nucleicoque codifican las proteínas de fusión de albúmina de la invención también están comprendidas en la invención, así como los vectores que contienen estos ácidos nucleicos, las células hospederas transformadas con estos vectores de ácidos nucleicos, y los métodos de hacer las proteínas de fusión de albúmina de la invención y de usar estos ácidos nucleicos, vectores, y/o células hospederas. Adicionalmente, la presente invención incluye composiciones farmacéuticas que comprenden las proteínas de fusión de albúmina y los métodos de tratamiento, prevención o mejoramiento de las enfermedades, trastornos o condiciones utilizando las proteínas de fusión de albúmina de la invención.The present invention comprises albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also included in the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making proteins. albumin fusion of the invention and using these nucleic acids, vectors, and / or host cells. Additionally, the present invention includes pharmaceutical compositions comprising albumin fusion proteins and methods of treatment, prevention or improvement of the diseases, disorders or conditions using the albumin fusion proteins of the invention.

EC2008008262A 2005-08-12 2008-03-12 ALBUMIN FUSION PROTEINS ECSP088262A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15

Publications (1)

Publication Number Publication Date
ECSP088262A true ECSP088262A (en) 2008-05-30

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008262A ECSP088262A (en) 2005-08-12 2008-03-12 ALBUMIN FUSION PROTEINS

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
WO2008033413A2 (en) * 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2450368A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
CN102378635A (en) 2009-01-16 2012-03-14 特瓦制药工业有限公司 Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia
KR101722961B1 (en) 2009-02-11 2017-04-04 알부메딕스 에이/에스 Albumin variants and conjugates
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP2493921B1 (en) * 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2012118042A1 (en) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター Medicinal agent for inhibiting metastasis of malignant tumor
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
DE202012012955U1 (en) 2011-10-21 2014-07-14 Abbvie Inc. A combination of at least two direct-acting antiviral agents (DAAs) for use in the treatment of HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CN104271150A (en) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (en) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド Factor VIII composition, and method of making and use of the composition
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
CN104661674A (en) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 Factor VIII complexes with XTEN and von Willebrand Factor protein, and uses thereof
HK1213767A1 (en) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
MX2015005363A (en) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Albumin variants.
WO2014127215A1 (en) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
US20160033523A1 (en) 2013-02-16 2016-02-04 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
CN113817069A (en) 2013-06-28 2021-12-21 比奥贝拉蒂治疗公司 Thrombin cleavable linker with XTEN and uses thereof
TW202003554A (en) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 Factor VIII-XTEN fusions and uses thereof
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Column virus inactivation procedures
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
BR112017007765B1 (en) 2014-10-14 2023-10-03 Halozyme, Inc COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING THE SAME
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
EA201890423A1 (en) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
JP7007261B2 (en) 2015-08-20 2022-01-24 アルブミディクス リミティド Albumin variants and conjugates
CN108367048B (en) 2015-10-02 2022-08-12 银溪制药股份有限公司 Bispecific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
CA3012695A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
EP3535585A1 (en) 2016-11-04 2019-09-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
MX2019006444A (en) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc HEMOPHILIC ARTHROPATHY TREATMENT METHODS USING CHEMERIC COAGULATION FACTORS.
JP2019536794A (en) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド Methods for inducing immune tolerance to coagulation factors
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
EA201991768A1 (en) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. FUSIONED PROTEINS BASED ON FACTOR IX AND METHODS OF PRODUCING THEM AND WAYS OF APPLICATION
JP2020517657A (en) * 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス Purification method of albumin fusion protein
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
PL3793588T3 (en) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
KR20210027426A (en) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 FGF21 formulation
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
JP7644007B2 (en) 2018-12-06 2025-03-11 バイオベラティブ セラピューティクス インコーポレイテッド Use of lentiviral vectors expressing factor IX
KR20220097891A (en) 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. Lentiviral vector formulation
MX2023000156A (en) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc METHODS FOR THE ELIMINATION OF FREE FACTOR VIII FROM PREPARATIONS OF LENTIVIRAL VECTORS MODIFIED TO EXPRESS SAID PROTEIN.
JPWO2022030580A1 (en) * 2020-08-06 2022-02-10
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
WO2024080306A1 (en) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and physiologically-active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
HUE027902T2 (en) * 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
MX2008001865A (en) 2008-04-15
AU2006280312A1 (en) 2007-02-22
WO2007021494A3 (en) 2007-07-26
NO20081233L (en) 2008-05-09
EP1924596A2 (en) 2008-05-28
KR20080071119A (en) 2008-08-01
EP1924596A4 (en) 2009-07-29
BRPI0614761A2 (en) 2009-05-19
JP2009504157A (en) 2009-02-05
CA2618476A1 (en) 2007-02-22
IL189246A0 (en) 2008-08-07
TNSN08064A1 (en) 2009-07-14
MA29836B1 (en) 2008-10-03
WO2007021494A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
ECSP088262A (en) ALBUMIN FUSION PROTEINS
MX2009002816A (en) Albumin fusion proteins.
CY1117401T1 (en) ALBUMIN Fusion Proteins
WO2007146038A3 (en) Albumin fusion proteins
JOP20190083B1 (en) FGF21 fusion polypeptides and their uses
WO2005003296A3 (en) Albumin fusion proteins
ES2353814T3 (en) RECOMBINANT N-GLYCOSILATED PROTEINS OF PROCEDURAL CELLS.
DOP2018000245A (en) GDF15 FUSION PROTEINS AND USES OF THESE
EA201171220A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
HN2006016512A (en) ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
MA32771B1 (en) FGF21 MUTANTS AND USES THEREOF
BR112019005587A2 (en) recombinant binding proteins and their use
UY29344A1 (en) HUMANIZED ANTIAMILOID ANTIBODIES
EA201001204A1 (en) METHODS AND COMPOSITIONS IN WHICH APPLY KLOTHO-FGF POLYPEPTIDES FUSED
CY1114265T1 (en) ALBUMIN Fusion Protein
CY1110860T1 (en) REVERSE TRANSLATION OF Poultry Telomerase
CR8978A (en) UNION DOMAIN FUSION PROTEINS
BRPI0511118A (en) untranscribed haemophilus influenzae polypeptides
MX362981B (en) Artificial nucleic acid molecules for improved protein or peptide expression.
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
WO2003030821A3 (en) Albumin fusion proteins
ATE533837T1 (en) MICROGININ-PRODUCING PROTEINS AND NUCLEIC ACIDS ENCODING A MICROGININ GENE CLUSTER AND METHODS FOR PRODUCING MICROGININS
ATE539086T1 (en) INTERLEUKIN-11 FUSION PROTEINS
ATE486127T1 (en) RESTORATION OF ACTIVITY OF 5-ENOLPYRUVYLSHIKIMAT-3-PHOSPHATE SYNTHASE BY FRAGMENT COMPLEMENTATION
DOP2006000117A (en) INTERFERON-BETA GENE THERAPY USING AN IMPROVED REGULATED EXPRESSION SYSTEM